[
  {
    "id": 1752807040429,
    "category": "疾病",
    "type": "single",
    "question": "按照癫痫发作类型的分类中，发作比例最高的是？",
    "options": [
      "全面性发作",
      "局灶性发作",
      "癫痫性痉挛",
      "反射性发作"
    ],
    "correct": [
      1
    ],
    "explanation": ""
  },
  {
    "id": 1752807040430,
    "category": "疾病",
    "type": "multiple",
    "question": "女性癫痫患者选择抗发作药物时需要注意哪些问题",
    "options": [
      "女性患者尤其关注药物对容貌的影响",
      "女性患者特殊的生理特点：月经，激素分泌等",
      "女性患者需面对生育问题",
      "女性患者肝肾代谢障碍"
    ],
    "correct": [
      0,
      1,
      2
    ],
    "explanation": ""
  },
  {
    "id": 1752807040431,
    "category": "疾病",
    "type": "multiple",
    "question": "婴幼儿及儿童癫痫患者选择抗发作药物时需要注意哪些问题",
    "options": [
      "婴幼儿肝脏和肾脏功能发育尚未完全成熟",
      "儿童正处于生长发育和学习的重要阶段",
      "儿童生长发育快，在标准体重范围内应按公斤体重计算给药量",
      "尤其关注药物\r\n对容貌的影响"
    ],
    "correct": [
      0,
      1,
      2
    ],
    "explanation": ""
  },
  {
    "id": 1752807040432,
    "category": "疾病",
    "type": "single",
    "question": "癫痫异常放电在发作初期就同时累及了双侧大脑半球，运动症状和发作的脑电图变化均为双侧性的是：",
    "options": [
      "局灶性发作进展为双侧强直-阵挛",
      "反射性发作",
      "局灶性发作",
      "全面性发作"
    ],
    "correct": [
      3
    ],
    "explanation": ""
  },
  {
    "id": 1752807040433,
    "category": "指南",
    "type": "single",
    "question": "根据卒中后癫痫（PSE）诊治的中国专家共识，加巴喷丁、（）、拉莫三嗪等不良反应发生率低，与抗凝药或抗血小板药物之间无显著相互作用，对血脂影响小，推荐作为PSE首选用药",
    "options": [
      "奥卡西平",
      "丙戊酸钠",
      "左乙拉西坦",
      "苯妥英钠"
    ],
    "correct": [
      2
    ],
    "explanation": ""
  },
  {
    "id": 1752807040434,
    "category": "指南",
    "type": "single",
    "question": "根据卒中后癫痫诊治的中国专家共识，最新有研究显示静脉使用（）在控制非惊厥性癫痫持续状态（NCSE）时显示出良好的安全性和有效性，推荐作为PSE患者NCSE的一线用药",
    "options": [
      "拉考沙胺",
      "左乙拉西坦",
      "唑吡坦",
      "苯巴比妥"
    ],
    "correct": [
      0
    ],
    "explanation": ""
  },
  {
    "id": 1752807040435,
    "category": "指南",
    "type": "single",
    "question": "（）治疗是最重要、最基本的治疗，也是大部分癫痫患者的首选治疗方式。",
    "options": [
      "抗癫痫发作药",
      "外科治疗",
      "生酮饮食",
      "物理治疗"
    ],
    "correct": [
      0
    ],
    "explanation": ""
  },
  {
    "id": 1752807040436,
    "category": "指南",
    "type": "single",
    "question": "抗癫痫发作药物不良反应管理指南 （2023）提出：4项队列研究结果表明拉莫三嗪和（） 是 目 前 认 为 妊 娠 期 服 用 较 为 安 全 的ASM（证据级别Ⅲ级）",
    "options": [
      "奥卡西平",
      "拉莫三嗪",
      "左乙拉西坦",
      "拉考沙胺"
    ],
    "correct": [
      2
    ],
    "explanation": ""
  },
  {
    "id": 1752807040437,
    "category": "指南",
    "type": "single",
    "question": "2022版癫痫伴抑郁诊断治疗的中国专家共识明确说明：哪种抗癫痫药对抑郁有正性作用",
    "options": [
      "拉考沙胺",
      "巴比妥类",
      "托吡酯",
      "左乙拉西坦"
    ],
    "correct": [
      0
    ],
    "explanation": ""
  },
  {
    "id": 1752807040438,
    "category": "指南",
    "type": "multiple",
    "question": "中国老年癫痫患者管理专家共识推荐：对合并有严重心脑血管基础病的老年癫痫患者,慎重使用钠通道阻滞剂和丙戊酸,可考虑选择(Ⅱ级证据,B级推荐)",
    "options": [
      "托吡酯",
      "拉莫三嗪",
      "左乙拉西坦",
      "拉考沙胺"
    ],
    "correct": [
      0,
      2,
      3
    ],
    "explanation": ""
  },
  {
    "id": 1752807040439,
    "category": "指南",
    "type": "single",
    "question": "强直-阵挛性癫痫持续（）分钟即为癫痫持续状态",
    "options": [
      "3分钟",
      "5分钟",
      "10分钟",
      "30分钟"
    ],
    "correct": [
      1
    ],
    "explanation": ""
  },
  {
    "id": 1752807040440,
    "category": "指南",
    "type": "multiple",
    "question": "根据2023版临床诊疗指南癫痫分册，以下属于惊厥性癫痫持续状态的二线治疗药物有",
    "options": [
      "咪达唑仑",
      "地西泮",
      "丙戊酸",
      "左乙拉西坦"
    ],
    "correct": [
      2,
      3
    ],
    "explanation": ""
  },
  {
    "id": 1752807040441,
    "category": "指南",
    "type": "multiple",
    "question": "按照2023版临床诊疗指南癫痫病分册，左乙拉西坦是（）发作类型的一线药物和添加药物？",
    "options": [
      "全面性强直-阵挛发作",
      "强直或失张力发作",
      "肌阵挛发作",
      "局灶性发作"
    ],
    "correct": [
      0,
      2,
      3
    ],
    "explanation": ""
  },
  {
    "id": 1752807040442,
    "category": "ASM",
    "type": "multiple",
    "question": "奥卡西平严重的不良反应包括",
    "options": [
      "皮疹",
      "Stevens-Johnson 综合征",
      "携带HLA-B*1502等位基因患者皮肤反应风险增加",
      "肾脏疾病"
    ],
    "correct": [
      0,
      1,
      2,
      3
    ],
    "explanation": ""
  },
  {
    "id": 1752807040443,
    "category": "ASM",
    "type": "single",
    "question": "伴发肝功能损害的癫痫患者首选抗痫药物是：",
    "options": [
      "丙戊酸钠",
      "奥卡西平",
      "开浦兰",
      "拉莫三嗪"
    ],
    "correct": [
      2
    ],
    "explanation": ""
  },
  {
    "id": 1752807040444,
    "category": "ASM",
    "type": "multiple",
    "question": "联合用药时要注意药物间相互作用，下面哪种药不是肝酶诱导剂：",
    "options": [
      "OXC",
      "CBZ",
      "LEV",
      "LCM"
    ],
    "correct": [
      2,
      3
    ],
    "explanation": ""
  },
  {
    "id": 1752807040445,
    "category": "ASM",
    "type": "multiple",
    "question": "奥卡西平可能会加重以下哪些类型的全面性发作加重",
    "options": [
      "全面强直阵挛",
      "强直或失张力",
      "失神发作",
      "肌阵挛发作"
    ],
    "correct": [
      0,
      1,
      2,
      3
    ],
    "explanation": ""
  },
  {
    "id": 1752807040446,
    "category": "ASM",
    "type": "multiple",
    "question": "奥卡西平可能会与以下哪些老年患者常用药物产生相互作用",
    "options": [
      "雌二醇",
      "乙炔雌二醇",
      "舍曲林",
      "辛伐他汀"
    ],
    "correct": [
      0,
      1,
      2,
      3
    ],
    "explanation": ""
  },
  {
    "id": 1752807040447,
    "category": "ASM",
    "type": "single",
    "question": "大规模研究显示左乙拉西坦的先天畸形发生低，丙戊酸先天畸形发生率高达（）%​",
    "options": [
      "0.028",
      "0.037",
      "0.056",
      "0.103"
    ],
    "correct": [
      3
    ],
    "explanation": ""
  },
  {
    "id": 1752807040448,
    "category": "ASM",
    "type": "multiple",
    "question": "丙戊酸可能会与以下哪些老年患者常用药物产生相互作用",
    "options": [
      "阿司匹林",
      "华法林",
      "利培酮",
      "西酞普兰"
    ],
    "correct": [
      0,
      1,
      2,
      3
    ],
    "explanation": ""
  },
  {
    "id": 1752807040449,
    "category": "ASM",
    "type": "multiple",
    "question": "以下哪些属于第三代ASMs",
    "options": [
      "乙琥胺",
      "唑尼沙胺",
      "拉考沙胺",
      "吡仑帕奈"
    ],
    "correct": [
      2,
      3
    ],
    "explanation": ""
  },
  {
    "id": 1752807040450,
    "category": "ASM",
    "type": "multiple",
    "question": "服用AEDs，尤其具有酶诱导作用的AEDs女性患者应该：",
    "options": [
      "补充Vit D和钙剂",
      "增加日光浴",
      "戒烟",
      "限制咖啡摄入"
    ],
    "correct": [
      0,
      1,
      2,
      3
    ],
    "explanation": ""
  },
  {
    "id": 1752807040451,
    "category": "开浦兰",
    "type": "single",
    "question": "左乙拉西坦适合老年患者使用，因为如下特点",
    "options": [
      "疗效确切，安全性好",
      "良好的药代动力学特点，没有临床意义的相互作用",
      "能改善认知和生活质量",
      "以上都是"
    ],
    "correct": [
      3
    ],
    "explanation": ""
  },
  {
    "id": 1752807040452,
    "category": "开浦兰",
    "type": "single",
    "question": "使用左乙拉西坦的女性患者哺乳，其药物乳汁/血浆比例",
    "options": [
      "高于安全阈值",
      "在安全阈值之内",
      "尚不明确",
      "与患者年龄相关"
    ],
    "correct": [
      1
    ],
    "explanation": ""
  },
  {
    "id": 1752807040453,
    "category": "开浦兰",
    "type": "single",
    "question": "左乙拉西坦适合女性癫痫患者使用，因为如下特点：",
    "options": [
      "对于青春期性激素等影响小",
      "妊娠妇女胎儿致畸风险低",
      "对于体重、骨代谢几乎不影响、长期使用能改善女性生活质量",
      "以上都是"
    ],
    "correct": [
      3
    ],
    "explanation": ""
  },
  {
    "id": 1752807040454,
    "category": "开浦兰",
    "type": "single",
    "question": "左乙拉西坦血药浓度达峰时间为？",
    "options": [
      "0.6-1.3h",
      "1.3-2.3h",
      "1.7-2.3h",
      "3h"
    ],
    "correct": [
      0
    ],
    "explanation": ""
  },
  {
    "id": 1752807040455,
    "category": "开浦兰",
    "type": "multiple",
    "question": "开浦兰针剂与口服给药如何转换？",
    "options": [
      "可以直接转换",
      "无需逐步增加或减少药物剂量",
      "每日总剂量和给药次数维持不变",
      "需逐步增加或减少药物剂量"
    ],
    "correct": [
      0,
      1,
      2
    ],
    "explanation": ""
  },
  {
    "id": 1752807040456,
    "category": "开浦兰",
    "type": "multiple",
    "question": "开浦兰针剂稀释液有",
    "options": [
      "0.9%氯化钠注射液",
      "5%葡萄糖注射液",
      "乳酸林格氏注射液",
      "10%葡萄糖注射液"
    ],
    "correct": [
      0,
      1,
      2
    ],
    "explanation": ""
  },
  {
    "id": 1752807040457,
    "category": "开浦兰",
    "type": "multiple",
    "question": "开浦兰针剂在成人及50kg以上儿童患者使用时，起始剂量，最大剂量",
    "options": [
      "500mg bid",
      "1000mg bid",
      "1500mg bid",
      "2000mg bid"
    ],
    "correct": [
      0,
      2
    ],
    "explanation": ""
  },
  {
    "id": 1752807040458,
    "category": "维派特",
    "type": "single",
    "question": "我国一项研究表明：患者初始或转换为LCM单药治疗局灶性癫痫、全面性癫痫，在随访12个月后有（）的癫痫儿童患者达到癫痫无发作。​",
    "options": [
      "0.221",
      "0.322",
      "0.465",
      "0.506"
    ],
    "correct": [
      2
    ],
    "explanation": ""
  },
  {
    "id": 1752807040459,
    "category": "维派特",
    "type": "single",
    "question": "研究表明：4-17岁儿童维派特联用任意ASM（）周，严重TEAEs发生率及停药率均与安慰剂相当",
    "options": [
      "4",
      "6",
      "10",
      "12"
    ],
    "correct": [
      2
    ],
    "explanation": ""
  },
  {
    "id": 1752807040460,
    "category": "维派特",
    "type": "single",
    "question": "部分性发作添加治疗时，基于疗效和耐受性，维派特可（  ）增加剂量50mg，一天2次，直至增至最高剂量（  ）mg/d：",
    "options": [
      "一周，200",
      "两周，200",
      "一周，400",
      "两周，600"
    ],
    "correct": [
      2
    ],
    "explanation": ""
  },
  {
    "id": 1752807040461,
    "category": "维派特",
    "type": "single",
    "question": "维派特成人单药治疗时，初始剂量为（）mg,bid；最高剂量每日（）mg",
    "options": [
      "50100",
      "50200",
      "100200",
      "100400"
    ],
    "correct": [
      3
    ],
    "explanation": ""
  },
  {
    "id": 1752807040462,
    "category": "维派特",
    "type": "single",
    "question": "维派特≥11kg，<30kg的儿童起始剂量为：",
    "options": [
      "1mg/kg，一日两次",
      "5mg/kg，一日两次",
      "10mg/kg，一日两次",
      "15mg/kg，一日两次"
    ],
    "correct": [
      0
    ],
    "explanation": ""
  },
  {
    "id": 1752807040463,
    "category": "维派特",
    "type": "single",
    "question": "对于维派特，以下描述错误的是：",
    "options": [
      "维派特给药剂量的95%通过尿液排泄",
      "轻至中度肝功能受损患者的最高推荐剂量为300mg/日",
      "轻中度肝功能受损的患者无需调整维派特的剂量",
      "未在重度肝功能受损患者中评价拉考沙胺的药代动力学"
    ],
    "correct": [
      2
    ],
    "explanation": ""
  },
  {
    "id": 1752807040464,
    "category": "维派特",
    "type": "multiple",
    "question": "老年患者使用维派特，描述正确的是：",
    "options": [
      "研究表明，65岁老年患者与<65岁患者相比，不良反应发生情况相当。",
      "老年患者(＞65岁)一般不需要减量",
      "心脏疾病合并老年患者，治疗需谨慎",
      "老年患者应考虑年龄相关的肾脏清除率下降"
    ],
    "correct": [
      0,
      1,
      2,
      3
    ],
    "explanation": ""
  },
  {
    "id": 1752807040465,
    "category": "维派特",
    "type": "single",
    "question": "目前中国申请的维派特口服溶液包装规格为：",
    "options": [
      "50ml:1g",
      "100ml:2g",
      "200ml:2g",
      "400ml:2g"
    ],
    "correct": [
      2
    ],
    "explanation": ""
  },
  {
    "id": 1752807040466,
    "category": "维派特",
    "type": "single",
    "question": "维派特两种剂型可等剂量等频率转换，临床使用更简单，50mg片剂=（）ml口服液",
    "options": [
      "1",
      "5",
      "10",
      "50"
    ],
    "correct": [
      1
    ],
    "explanation": ""
  },
  {
    "id": 1752807040467,
    "category": "维派特",
    "type": "multiple",
    "question": "目前中国申请的维派特片剂包装规格为：",
    "options": [
      "50mg， 14片",
      "100mg，14片",
      "100mg，28片",
      "100mg，56片"
    ],
    "correct": [
      0,
      1,
      3
    ],
    "explanation": ""
  },
  {
    "id": 1752807040468,
    "category": "ASM",
    "type": "multiple",
    "question": "钠离子通道三种生理状态，包括：",
    "options": [
      "失活",
      "关闭",
      "开放",
      "慢失活"
    ],
    "correct": [
      0,
      1,
      2
    ],
    "explanation": ""
  },
  {
    "id": 1752807040469,
    "category": "维派特",
    "type": "single",
    "question": "中日注册研究中200mg/d剂量时，维派特皮疹发生率：",
    "options": [
      "0.027",
      "0.017",
      "0",
      "0.015"
    ],
    "correct": [
      2
    ],
    "explanation": ""
  },
  {
    "id": 1752807040470,
    "category": "维派特",
    "type": "single",
    "question": "中日注册研究中400mg/d剂量时，维派特皮疹发生率：",
    "options": [
      "2.70%",
      "1.70%",
      "0",
      "1.50%"
    ],
    "correct": [
      1
    ],
    "explanation": ""
  },
  {
    "id": 1752807040471,
    "category": "维派特",
    "type": "multiple",
    "question": "华西医院牵头的一项真实世界研究表明：LCM作为添加药物，在第五次随访时（）评分和（）评分显著下降",
    "options": [
      "焦虑",
      "躁狂",
      "痴呆",
      "抑郁"
    ],
    "correct": [
      0,
      3
    ],
    "explanation": ""
  },
  {
    "id": 1752807040472,
    "category": "维派特",
    "type": "single",
    "question": "德国一项纳入333参考文献的临床综述表明：相比其他ASM，拉考沙胺对睡眠、行为、精神无负面影响，对（）有改善作用",
    "options": [
      "意识水平",
      "智力",
      "执行力",
      "认知"
    ],
    "correct": [
      3
    ],
    "explanation": ""
  },
  {
    "id": 1752807040473,
    "category": "疾病",
    "type": "single",
    "question": "按照Hoehn‐Yahr分级， （）级定义为早期帕金森",
    "options": [
      "0-1.0",
      "0-2.0",
      "1.0-2.5",
      "1.0-3.0"
    ],
    "correct": [
      2
    ],
    "explanation": ""
  },
  {
    "id": 1752807040474,
    "category": "疾病",
    "type": "multiple",
    "question": "按照Hoehn‐Yahr分级， （）级定义为双侧肢体受累",
    "options": [
      "0",
      "1.0",
      "2.0",
      "3.0"
    ],
    "correct": [
      2,
      3
    ],
    "explanation": ""
  },
  {
    "id": 1752807040475,
    "category": "指南",
    "type": "single",
    "question": "2020《中国帕金森病治疗指南(第四版)》建议帕金森（）诊断，（）治疗",
    "options": [
      "早，早期",
      "早，延迟治疗",
      "早，1.5年后治疗",
      "晚，早期"
    ],
    "correct": [
      0
    ],
    "explanation": ""
  },
  {
    "id": 1752807040476,
    "category": "指南",
    "type": "multiple",
    "question": "2020《中国帕金森病治疗指南(第四版)》提出帕金森的药物治疗目标为：",
    "options": [
      "改善症状",
      "避免/降低不良反应",
      "提高生活质量",
      "提高工作能力"
    ],
    "correct": [
      0,
      1,
      2,
      3
    ],
    "explanation": ""
  },
  {
    "id": 1752807040477,
    "category": "优普洛",
    "type": "multiple",
    "question": "优普洛贴片的结构包括",
    "options": [
      "背衬层",
      "自粘合基质层",
      "保护层",
      "贴膜层"
    ],
    "correct": [
      0,
      1,
      2
    ],
    "explanation": ""
  },
  {
    "id": 1752807040478,
    "category": "优普洛",
    "type": "single",
    "question": "优普洛贴片的厚度为：",
    "options": [
      "30 µm",
      "50 µm",
      "80 µm",
      "100 µm"
    ],
    "correct": [
      1
    ],
    "explanation": ""
  },
  {
    "id": 1752807040479,
    "category": "优普洛",
    "type": "multiple",
    "question": "关于优普洛，以下说法正确的是：",
    "options": [
      "24小时药效持续稳定",
      "不通过胃肠道吸收",
      "可显著改善PD患者运动症状",
      "安全性和耐受性良好"
    ],
    "correct": [
      0,
      1,
      2,
      3
    ],
    "explanation": ""
  },
  {
    "id": 1752807040480,
    "category": "优普洛",
    "type": "single",
    "question": "协和医院张振馨教授牵头的，针对中国早期人群的RCT研究中演示：优普洛第（）周开始改善症状，第（）周达到最大疗效",
    "options": [
      "2，3",
      "3，3",
      "3，5",
      "3，7"
    ],
    "correct": [
      3
    ],
    "explanation": ""
  },
  {
    "id": 1752807040481,
    "category": "优普洛",
    "type": "single",
    "question": "优普洛的适应症为：适用于早期特发性帕金森病症状及体征的单药治疗，或与（）联合用于病程中的各个阶段",
    "options": [
      "普拉克索",
      "司来吉兰",
      "左旋多巴",
      "苯海索"
    ],
    "correct": [
      2
    ],
    "explanation": ""
  },
  {
    "id": 1752807040482,
    "category": "优普洛",
    "type": "single",
    "question": "提前6个月使用优普洛治疗，可使患者回到基线时间延长（）年​",
    "options": [
      "半年",
      "1年",
      "2年",
      "3年"
    ],
    "correct": [
      2
    ],
    "explanation": ""
  }
]